Solid lipid nanoparticles (SLNs) conjugated to a cyclic peptide iRGD (CCRGDKGPDC) deliver small interfering RNAs (siRNAs) against both PD-L1 and epidermal growth factor receptor (EGFR) for targeted and immunotherapy against GBM [52]. Here, EGFR is linked to glioblastoma.